

# Paul Russo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1191027/publications.pdf>

Version: 2024-02-01

198  
papers

11,810  
citations

53660

45  
h-index

31759

101  
g-index

211  
all docs

211  
docs citations

211  
times ranked

14087  
citing authors

#	ARTICLE	IF	CITATIONS
1	The association between modifiable perioperative parameters and renal function after nephrectomy. BJU International, 2022, 129, 380-386.	1.3	2
2	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	13.5	223
3	Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. European Urology, 2022, 81, 570-573.	0.9	22
4	Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. European Urology Focus, 2022, 8, 1278-1288.	1.6	11
5	Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome. Modern Pathology, 2022, 35, 825-835.	2.9	14
6	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. Cancer Discovery, 2022, 12, 2308-2329.	7.7	7
7	The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. European Urology, 2021, 79, 468-477.	0.9	35
8	EDITORIAL COMMENT. Urology, 2021, 148, 190.	0.5	0
9	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. European Urology Focus, 2021, 7, 381-389.	1.6	28
10	Therapy-relevant gene signatures in the high risk localized renal cell carcinoma setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT).. Journal of Clinical Oncology, 2021, 39, 353-353.	0.8	0
11	A qualitative framework of non-selection factors for cytoreductive nephrectomy. World Journal of Urology, 2021, 39, 3359-3365.	1.2	3
12	The spinal distribution of metastatic renal cell carcinoma: Support for locoregional rather than arterial hematogenous mode of early bony dissemination. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 196.e9-196.e14.	0.8	1
13	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 2910-2919.	3.2	45
14	Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. Cancer Cell, 2021, 39, 662-677.e6.	7.7	179
15	Resource-efficient pooled sequencing expands translational impact in solid tumors. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2021, 19, 18-23.	0.1	1
16	Open partial nephrectomy with kidney split: Effective surgical approach to resect completely endophytic tumors. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 371.e1-371.e5.	0.8	0
17	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 5595-5606.	3.2	12
18	Functional and Oncological Outcomes of Renal Surgery for Hilar Tumors: Informing the Decisions in Risk-Adapted Management. Urology, 2021, , .	0.5	0

#	ARTICLE	IF	CITATIONS
19	Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Cancer</i> , 2021, 127, 3946-3956.	2.0	12
20	A comparison of oncologic and functional outcomes in patients with pt3a renal cell carcinoma treated with partial and radical nephrectomy. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2021, 47, 777-783.	0.7	6
21	Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma – An exploratory analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 791.e17-791.e24.	0.8	3
22	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. <i>European Urology Oncology</i> , 2021, 4, 993-1000.	2.6	16
23	Value of Partial Nephrectomy for Renal Cortical Tumors of cT2 or Greater Stage: A Risk-benefit Analysis of Renal Function Preservation Versus Increased Postoperative Morbidity. <i>European Urology Oncology</i> , 2020, 3, 365-371.	2.6	10
24	The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience. <i>Urology</i> , 2020, 136, 169-175.	0.5	9
25	Primary Renal Well-differentiated Neuroendocrine Tumor Extending Into the Inferior Vena Cava. <i>Urology</i> , 2020, 135, e2-e4.	0.5	0
26	Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 283-293.	5.1	121
27	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. <i>European Urology Oncology</i> , 2020, 3, 47-56.	2.6	20
28	Preoperative nomogram predicting 12-year probability of metastatic renal cancer – evaluation in a contemporary cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 853.e1-853.e7.	0.8	6
29	Sarcomatoid renal cell carcinoma: biology, natural history and management. <i>Nature Reviews Urology</i> , 2020, 17, 659-678.	1.9	76
30	Upper Tract Urothelial Carcinoma in a Patient With Horseshoe Kidney. <i>Urology</i> , 2020, 142, e20-e24.	0.5	4
31	Impact of intraoperative opioid and adjunct analgesic use on renal cell carcinoma recurrence: role for onco-anaesthesia. <i>British Journal of Anaesthesia</i> , 2020, 125, e402-e404.	1.5	15
32	Predictors of long-term renal function after kidney surgery for patients with preoperative chronic kidney disease. <i>Canadian Urological Association Journal</i> , 2020, 15, E103-E109.	0.3	0
33	Renal cell carcinoma: Associations between tumor imaging features and epidemiological risk factors. <i>European Journal of Radiology</i> , 2020, 129, 109096.	1.2	5
34	An evaluation of the role of tumor load in cytoreductive nephrectomy. <i>Canadian Urological Association Journal</i> , 2020, 14, E625-E630.	0.3	1
35	Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. <i>Scientific Reports</i> , 2020, 10, 701.	1.6	21
36	EDITORIAL COMMENT. <i>Urology</i> , 2020, 136, 167-168.	0.5	0

#	ARTICLE	IF	CITATIONS
37	Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 387-394.	0.9	32
38	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. <i>Clinical Cancer Research</i> , 2020, 26, 3629-3640.	3.2	30
39	Comparison of Cancer Specific Outcomes following Minimally Invasive and Open Surgical Resection of Early Stage Kidney Cancer from a National Cancer Registry. <i>Journal of Urology</i> , 2020, 203, 1094-1100.	0.2	9
40	Editorial Comment. <i>Journal of Urology</i> , 2020, 204, 441-441.	0.2	0
41	Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 373-379.e4.	0.9	33
42	The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 916-923.	0.8	8
43	Phase III Trial of Intravenous Mannitol Versus Placebo During Nephron-sparing Surgery: Post Hoc Analysis of 3-yr Outcomes. <i>European Urology Focus</i> , 2019, 5, 977-979.	1.6	5
44	Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 811.e9-811.e16.	0.8	6
45	Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 268-274.e1.	0.9	29
46	Juxtaglomerular Cell Tumor: A Rare, Curable Cause of Hypertension in a Young Patient. <i>Urology</i> , 2019, 134, 42-44.	0.5	4
47	Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1983-1992.	0.5	18
48	The prognostic significance of nodal disease burden in patients with lymph node metastases from renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 302.e1-302.e6.	0.8	11
49	Editorial Comment on: Treatment Trends and Long-Term Survival Associated with Cryotherapy and Partial Nephrectomy for Small Renal Masses in the National Cancer Database Using Propensity Score Matching by Kitley et al.(From: Kitley W, Sulek J, Sundaram C, et al. <i>J Endourol</i> 2019;33:408â€“414; DOI: 10.7843/14 rgBT)		
50	Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e678-e688.	0.9	41
51	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
52	Epidemiology of Renal Cell Carcinoma. <i>European Urology</i> , 2019, 75, 74-84.	0.9	917
53	Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2019, 5, 642-649.	1.6	40
54	Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. <i>ELife</i> , 2019, 8, .	2.8	31

#	ARTICLE	IF	CITATIONS
55	Editorial Comment. Journal of Urology, 2019, 201, 708-708.	0.2	0
56	Editorial Comment. Journal of Urology, 2019, 202, 1125-1126.	0.2	0
57	Cystic Renal Cell Carcinoma: A Report on Outcomes of Surgery and Active Surveillance in Patients Retrospectively Identified on Pretreatment Imaging. Journal of Urology, 2018, 200, 275-282.	0.2	31
58	The Effect of Patient and Surgical Characteristics on Renal Function After Partial Nephrectomy. Clinical Genitourinary Cancer, 2018, 16, 191-196.	0.9	7
59	Progression from tubulovillous adenoma to high-grade adenocarcinoma in Indiana pouch urinary diversion. Urology Case Reports, 2018, 16, 129-131.	0.1	1
60	Editorial Comment. Journal of Urology, 2018, 199, 400-400.	0.2	0
61	Importance of wide resection in adult spermatic cord sarcomas: Report on oncologic outcomes at a single institution. Journal of Surgical Oncology, 2018, 117, 1464-1468.	0.8	6
62	Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma. European Urology Focus, 2018, 4, 100-105.	1.6	14
63	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. European Urology Focus, 2018, 4, 986-994.	1.6	29
64	Intravenous Mannitol Versus Placebo During Partial Nephrectomy in Patients with Normal Kidney Function: A Double-blind, Clinically-integrated, Randomized Trial. European Urology, 2018, 73, 53-59.	0.9	41
65	Editorial Comment. Journal of Urology, 2018, 199, 59-59.	0.2	0
66	Long-Term Renal Function Recovery following Radical Nephrectomy for Kidney Cancer: Results from a Multicenter Confirmatory Study. Journal of Urology, 2018, 199, 921-926.	0.2	34
67	Renal function recovery after radical nephroureterectomy for upper tract urothelial carcinoma. World Journal of Urology, 2018, 36, 257-263.	1.2	11
68	Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Urologic Oncology: Seminars and Original Investigations, 2018, 36, 79.e11-79.e17.	0.8	14
69	The contemporary role of lymph node dissection in the management of renal cell carcinoma. Therapeutic Advances in Urology, 2018, 10, 335-342.	0.9	8
70	Cytoreductive Nephrectomy – Patient Selection Is Key. New England Journal of Medicine, 2018, 379, 481-482.	13.9	88
71	The natural history of large renal masses followed on observation. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 362.e17-362.e21.	0.8	14
72	The association of renal cell carcinoma with gastrointestinal stromal tumors. Journal of Surgical Oncology, 2018, 117, 1716-1720.	0.8	6

#	ARTICLE	IF	CITATIONS
73	Obstructive sleep apnea and Fuhrman grade in patients with clear cell renal cell carcinoma treated surgically. <i>World Journal of Urology</i> , 2017, 35, 51-56.	1.2	13
74	Differentiation of Clear Cell Renal Cell Carcinoma From Other Renal Cortical Tumors by Use of a Quantitative Multiparametric MRI Approach. <i>American Journal of Roentgenology</i> , 2017, 208, W85-W91.	1.0	40
75	Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 668-680.	0.8	262
76	Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma. <i>Cancer</i> , 2017, 123, 2452-2458.	2.0	12
77	Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 532.e7-532.e13.	0.8	25
78	Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection. <i>Nature Communications</i> , 2017, 8, 15165.	5.8	61
79	Editorial Comment. <i>Journal of Urology</i> , 2017, 198, 35-35.	0.2	0
80	Influence of renal biopsy results on the management of small kidney cancers in older patients: Results from a population-based cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 604.e1-604.e9.	0.8	8
81	The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 35.e1-35.e5.	0.8	21
82	Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. <i>European Urology Focus</i> , 2017, 3, 590-598.	1.6	31
83	Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , 2017, 3, 421-427.	1.6	43
84	Estimated glomerular filtration rate, renal scan and volumetric assessment of the kidney before and after partial nephrectomy: a review of the current literature. <i>Minerva Urology and Nephrology</i> , 2017, 69, 539-547.	1.3	19
85	Nephrometry scores and perioperative outcomes following robotic partial nephrectomy. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2017, 43, 1075-1083.	0.7	11
86	Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients. <i>PLoS ONE</i> , 2017, 12, e0180350.	1.1	2
87	Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 276-278.	2.5	34
88	Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3916-3923.	0.8	316
89	Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. <i>JCI Insight</i> , 2017, 2, .	2.3	89
90	Patterns of surveillance imaging after nephrectomy in the Medicare population. <i>BJU International</i> , 2016, 117, 280-286.	1.3	12

#	ARTICLE	IF	CITATIONS
91	Editorial Comment. Urology, 2016, 93, 129.	0.5	0
92	Second primary malignancies in renal cortical neoplasms: an updated evaluation from a single institution. World Journal of Urology, 2016, 34, 1667-1672.	1.2	6
93	Surgical Treatment of Tumors Involving Kidneys With Fusion Anomalies: A Contemporary Series. Urology, 2016, 98, 97-102.	0.5	22
94	Reply to Williamson S.R. What is the malignant potential of clear cell papillary renal cell carcinoma? Urol Oncol 2016; 34: 420. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 581-582.	0.8	1
95	Delayed systemic treatment in metastatic renal-cell carcinoma. Lancet Oncology, The, 2016, 17, 1187-1189.	5.1	2
96	Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. Journal of Surgical Oncology, 2016, 114, 764-768.	0.8	26
97	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology, 2016, 17, 231.	3.8	746
98	Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nature Communications, 2016, 7, 13131.	5.8	140
99	Complete metastasectomy for renal cell carcinoma: Comparison of five solid organ sites. Journal of Surgical Oncology, 2016, 114, 375-379.	0.8	39
100	Low yield of surveillance imaging after surgery for T1 kidney cancer. World Journal of Urology, 2016, 34, 949-953.	1.2	4
101	Clear Cell Renal Cell Carcinoma: Associations Between CT Features and Patient Survival. American Journal of Roentgenology, 2016, 206, 1023-1030.	1.0	33
102	Renal cell carcinoma: A nomogram for the CT imaging-inclusive prediction of indolent, non-clear cell renal cortical tumours. European Journal of Cancer, 2016, 59, 57-64.	1.3	15
103	The effect of delaying nephrectomy on oncologic outcomes in patients with renal tumors greater than 4cm. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 239.e1-239.e8.	0.8	25
104	Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 259.e1-259.e8.	0.8	56
105	Use of DWI in the Differentiation of Renal Cortical Tumors. American Journal of Roentgenology, 2016, 206, 100-105.	1.0	61
106	An Arterial Based Complexity (ABC) Scoring System to Assess the Morbidity Profile of Partial Nephrectomy. European Urology, 2016, 69, 72-79.	0.9	75
107	The Prognostic Impact of a Positive Vascular Margin on pT3 Clear Cell Renal Cell Carcinoma. Journal of Urology, 2016, 195, 264-269.	0.2	15
108	Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. European Urology, 2016, 69, 646-657.	0.9	249

#	ARTICLE	IF	CITATIONS
109	Histologic subtype impacts cancer-specific survival in patients with sarcomatoid-variant renal cell carcinoma treated surgically. <i>World Journal of Urology</i> , 2016, 34, 539-544.	1.2	12
110	Understanding the genomic underpinnings of metastatic chromophobe renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 513-513.	0.8	1
111	The immune landscape of renal cell carcinoma and its association with intratumoral clonality.. <i>Journal of Clinical Oncology</i> , 2016, 34, 605-605.	0.8	0
112	Comparing surgical tissue versus biopsy tissue in the development of a clear cell renal cell carcinoma xenograft model.. <i>Journal of Clinical Oncology</i> , 2016, 34, 519-519.	0.8	0
113	Single-institutional analysis of patients with clear-cell papillary renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 512-512.	0.8	0
114	Management of Small Kidney Cancers in the New Millennium. <i>JAMA Surgery</i> , 2015, 150, 664.	2.2	75
115	Long-Term Survival Rates after Resection for Locally Advanced Kidney Cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 Experience. <i>Journal of Urology</i> , 2015, 193, 1911-1917.	0.2	40
116	TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. <i>Modern Pathology</i> , 2015, 28, 845-853.	2.9	127
117	Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy. <i>Journal of Urology</i> , 2015, 193, 436-442.	0.2	27
118	Editorial Comment. <i>Urology</i> , 2015, 85, 1422-1423.	0.5	0
119	Pathological Stage T3a Significantly Increases Disease Recurrence across All Tumor Sizes in Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 194, 310-315.	0.2	36
120	A Literature Review of Renal Surgical Anatomy and Surgical Strategies for Partial Nephrectomy. <i>European Urology</i> , 2015, 68, 980-992.	0.9	206
121	Reply. <i>Urology</i> , 2015, 85, 603-604.	0.5	0
122	Cost Comparison of Open and Robotic Partial Nephrectomy Using a Short Postoperative Pathway. <i>Urology</i> , 2015, 85, 596-604.	0.5	30
123	Partial nephrectomy for renal tumors in solitary kidneys: postoperative renal function dynamics. <i>World Journal of Urology</i> , 2015, 33, 2023-2029.	1.2	12
124	Partial and Radical Nephrectomy for Unilateral Synchronous Multifocal Renal Cortical Tumors. <i>Urology</i> , 2015, 85, 1404-1410.	0.5	19
125	Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. <i>Journal of Urology</i> , 2015, 194, 304-309.	0.2	28
126	New Chronic Kidney Disease and Overall Survival After Nephrectomy for Small Renal Cortical Tumors. <i>Urology</i> , 2015, 86, 1137-1145.	0.5	34



#	ARTICLE	IF	CITATIONS
127	Subcentimeter Pulmonary Nodules are Not Associated with Disease Progression in Patients with Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 776-782.	0.2	18
128	Proteomic stratification of clear cell renal cell carcinoma utilizing The Cancer Genome Atlas (TCGA) with external validation.. <i>Journal of Clinical Oncology</i> , 2015, 33, 406-406.	0.8	0
129	Association between visceral and subcutaneous adiposity and clinicopathological outcomes in non-metastatic clear cell renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2014, 8, 675.	0.3	22
130	Neutrophil-Lymphocyte Ratio in Small Renal Masses. <i>ISRN Urology</i> , 2014, 2014, 1-5.	1.5	9
131	Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience. <i>International Scholarly Research Notices</i> , 2014, 2014, 1-6.	0.9	12
132	Editorial Comment. <i>Urology</i> , 2014, 84, 1406-1407.	0.5	0
133	Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-associated Renal Cancer. <i>American Journal of Surgical Pathology</i> , 2014, 38, 627-637.	2.1	223
134	Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 1955-1964.	3.2	208
135	Open Mini-Flank Partial Nephrectomy: An Essential Contemporary Operation. <i>Korean Journal of Urology</i> , 2014, 55, 557.	1.2	13
136	Handling patients with growing small renal masses. <i>Canadian Urological Association Journal</i> , 2014, 8, 28.	0.3	0
137	Impact of Recurrent Copy Number Alterations and Cancer Gene Mutations on the Predictive Accuracy of Prognostic Models in Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 192, 24-29.	0.2	15
138	The Association between Statin Medication and Progression after Surgery for Localized Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 914-919.	0.2	39
139	Clinicopathologic Features of Renomedullary Interstitial Cell Tumor Presenting as the Main Solid Renal Mass. <i>Urology</i> , 2014, 83, 1104-1106.	0.5	8
140	To Clamp or Not To Clamp the Main Renal Artery: The Debate Continues. <i>European Urology</i> , 2014, 66, 720-721.	0.9	1
141	CKD and the Risk of Incident Cancer. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2327-2334.	3.0	207
142	Impact of a Common Clinical Pathway on Length of Hospital Stay in Patients Undergoing Open and Minimally Invasive Kidney Surgery. <i>Journal of Urology</i> , 2014, 191, 1225-1230.	0.2	32
143	Adult Prostate Sarcoma: The Memorial Sloan Kettering Experience. <i>Urology</i> , 2014, 84, 624-628.	0.5	38
144	Editorial Comment. <i>Urology</i> , 2014, 83, 849-850.	0.5	0

#	ARTICLE	IF	CITATIONS
145	Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. <i>European Urology</i> , 2014, 66, 577-583.	0.9	76
146	Long-term mortality in patients with germ cell tumors: Effect of primary cancer site on cause of death. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 26.e9-26.e15.	0.8	23
147	Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 395-395.	0.8	1
148	Integrated analysis of metastatic disease in clear cell renal cell carcinoma: A collaborative TCGA analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 432-432.	0.8	0
149	Neutrophil-lymphocyte ratio in small renal masses.. <i>Journal of Clinical Oncology</i> , 2014, 32, 522-522.	0.8	0
150	Association of baseline health and gender with small renal mass pathology.. <i>Journal of Clinical Oncology</i> , 2014, 32, 515-515.	0.8	0
151	End Stage and Chronic Kidney Disease: Associations with Renal Cancer. <i>Frontiers in Oncology</i> , 2012, 2, 28.	1.3	56
152	The Role of Surgery in the Management of Early-Stage Renal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 737-752.	0.9	23
153	Oncological outcomes of partial nephrectomy for renal carcinoma greater than 4cm. <i>Current Opinion in Urology</i> , 2011, 21, 362-367.	0.9	6
154	Sarcomatoid-variant Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 454-459.	0.6	91
155	Chromophobe Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2011, 35, 962-970.	2.1	115
156	Open partial nephrectomy. Personal technique and current outcomes. <i>Archivos Espanoles De Urologia</i> , 2011, 64, 571-93.	0.1	10
157	Multi-modal treatment for metastatic renal cancer: the role of surgery. <i>World Journal of Urology</i> , 2010, 28, 295-301.	1.2	46
158	Partial nephrectomy for renal cancer: Part I. <i>BJU International</i> , 2010, 105, 1206-1220.	1.3	32
159	Partial nephrectomy for renal cancer (part II): the impact of renal ischaemia, patient preparation, surgical approaches, management of complications and utilization. <i>BJU International</i> , 2010, 105, 1494-1507.	1.3	21
160	Editorial Comment. <i>Urology</i> , 2009, 73, 1082.	0.5	2
161	Editorial Comment. <i>Urology</i> , 2009, 73, 1297-1298.	0.5	2
162	Functional preservation in patients with renal cortical tumors: The rationale for partial nephrectomy. <i>Current Urology Reports</i> , 2008, 9, 15-21.	1.0	12

#	ARTICLE	IF	CITATIONS
163	Survival rates after resection for localized kidney cancer: 1989 to 2004. <i>Cancer</i> , 2008, 113, 84-96.	2.0	85
164	A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder. <i>Cancer</i> , 2008, 113, 2471-2477.	2.0	239
165	The Medical and Oncological Rationale for Partial Nephrectomy for the Treatment of T1 Renal Cortical Tumors. <i>Urologic Clinics of North America</i> , 2008, 35, 635-643.	0.8	70
166	Surgical Intervention in Patients with Metastatic Renal Cancer: Metastasectomy and Cytoreductive Nephrectomy. <i>Urologic Clinics of North America</i> , 2008, 35, 679-686.	0.8	38
167	Is laparoscopic partial nephrectomy as effective as open partial nephrectomy in patients with renal cell carcinoma?. <i>Nature Reviews Urology</i> , 2008, 5, 12-13.	1.4	2
168	Open partial nephrectomy: an essential operation with an expanding role. <i>Current Opinion in Urology</i> , 2007, 17, 309-315.	0.9	27
169	Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer. <i>Scientific World Journal</i> , The, 2007, 7, 768-778.	0.8	43
170	Partial nephrectomy achieves local tumor control and prevents chronic kidney disease. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1745-1751.	1.1	9
171	Renal tumours: developing understanding leads to developments in surgical treatment. <i>BJU International</i> , 2006, 97, 9-10.	1.3	1
172	Renal cryoablation: a new treatment in need of careful clinical investigation. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 286-287.	4.3	0
173	Surgical intervention in patients with metastatic renal cancer: current status of metastasectomy and cytoreductive nephrectomy. <i>Nature Reviews Urology</i> , 2004, 1, 26-30.	1.4	12
174	Orthotopic Urinary Diversion After Cystectomy For Bladder Cancer: Implications For Cancer Control And Patterns Of Disease Recurrence. <i>Journal of Urology</i> , 2003, 169, 177-181.	0.2	97
175	Metastatic Carcinoid Tumor of the Prostate. <i>Journal of Urology</i> , 2002, 167, 2526-2527.	0.2	27
176	RE: LAPAROSCOPIC RADICAL NEPHRECTOMY: CANCER CONTROL FOR RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2002, 168, 1109-1109.	0.2	0
177	Partial nephrectomy: The rationale for expanding the indications. <i>Annals of Surgical Oncology</i> , 2002, 9, 680-687.	0.7	64
178	Partial nephrectomy: The rationale for expanding the indications. , 2002, 9, 680.		4
179	Localized renal cell carcinoma. <i>Current Treatment Options in Oncology</i> , 2001, 2, 447-455.	1.3	29
180	Urologic complications of major pelvic surgery. , 2000, 18, 216-228.		14

#	ARTICLE	IF	CITATIONS
181	The Type of Urinary Diversion After Radical Cystectomy Significantly Impacts on the Patient's Quality of Life. <i>Annals of Surgical Oncology</i> , 2000, 7, 4-8.	0.7	62
182	Urinary Diversion After Total Pelvic Exenteration for Rectal Cancer. <i>Annals of Surgical Oncology</i> , 1999, 6, 732-738.	0.7	54
183	The role of surgery in the treatment of clinically isolated adrenal metastasis. <i>Cancer</i> , 1998, 82, 389-394.	2.0	251
184	Bilateral non-familial renal cell carcinoma. <i>Annals of Surgical Oncology</i> , 1998, 5, 548-552.	0.7	77
185	Results of laparoscopic pelvic lymphadenectomy in patients at high risk for nodal metastases from prostate cancer. <i>Annals of Surgical Oncology</i> , 1998, 5, 173-180.	0.7	16
186	MULTIPLE PRIMARY MALIGNANCIES IN RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 1998, 160, 1255-1259.	0.2	98
187	The role of surgery in the treatment of clinically isolated adrenal metastasis. , 1998, 82, 389.		14
188	Pathologic findings at the time of nephrectomy for renal mass. <i>Annals of Surgical Oncology</i> , 1997, 4, 570-574.	0.7	90
189	Nephrectomy during operative management of retroperitoneal sarcoma. <i>Annals of Surgical Oncology</i> , 1997, 4, 421-424.	0.7	82
190	Ureteral decompression in advanced nonurologic malignancies. <i>Annals of Surgical Oncology</i> , 1996, 3, 393-399.	0.7	53
191	TRPM-2 gene expression in normal rat ventral prostate following castration and exposure to diethylstilbestrol, flutamide, MK-906 (finasteride), and coumarin. <i>Prostate</i> , 1994, 24, 237-243.	1.2	19
192	The role of pelvic lymphadenectomy and radical cystectomy for lymph node positive bladder cancer. The memorial sloan-kettering cancer center experience. <i>Cancer</i> , 1994, 73, 3020-3028.	2.0	84
193	Myocutaneous Flaps in Genitourinary Oncology. <i>Journal of Urology</i> , 1994, 151, 920-924.	0.2	13
194	Positive Urinary Cytology Following a Complete Response to Intravesical Bacillus Calmette-Guerin Therapy: Pattern of Recurrence. <i>Journal of Urology</i> , 1994, 152, 382-387.	0.2	29
195	High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. <i>Cancer</i> , 1992, 69, 550-556.	2.0	105
196	Salvage chemotherapy for patients with germ cell tumors. The memorial sloan-kettering cancer center experience (1979-1989). <i>Cancer</i> , 1991, 67, 1305-1310.	2.0	127
197	The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. <i>Cancer</i> , 1990, 66, 2476-2481.	2.0	119
198	Histopathologic and Ultrastructural Correlates of Tumor Growth Suppression by High Energy Shock Waves. <i>Journal of Urology</i> , 1987, 137, 338-341.	0.2	79